Oxford Genome Sciences Recruits Senior Industry Professionals to Drive its Personalized Medicines Development
Complete the form below to unlock access to ALL audio articles.
Oxford Genome Sciences (UK) Ltd “OGeS” announces today that it has appointed several senior pharmaceutical industry professionals as it builds its organization to support its development of ersonalised medicines.
OGeS is focused on developing new personalized medicines for the treatment of cancer based on capitalizing on its Oxford Genome Anatomy Project (OGAP®), which is one of the world’s largest proprietary collections of proteins with relevance to clinical medicine.
The two new recruits to the OGeS team in the UK are: Dr Benjamin Reed has joined OGeS’ Biomarker Services Division as Business Development Director. Dr Reed previously worked at Ciphergen Biosystems for 6 years and has extensive knowledge and experience in the field of biomarker discovery. He was responsible for providing proteomics equipment as well as analytical services to academic institutes and pharmaceutical and biotechnology companies.
Dr David Bell, PhD, has joined OGeS as Head of Mass Spectrometry Operations. Dr Bell has joined the company from Glaxo SmithKline where he worked for 18 years. At Glaxo SmithKline, he developed and applied mass spectrometric methods to drug discovery and development processes. He has experience of a wide range of instrumentation, particularly LC/MS/MS & applications in the pharmaceutical industry. Latterly, he was involved in biomarker discovery and target identification using a range of proteomics approaches.
David has co-authored over 20 publications on the utilization of mass spectrometry in pharmaceutical R&D.
In the US, OGeS has established a pre-clinical group in San Francisco in order to leverage its existing strategic alliances with Medarex and Biosite and to advance the company growing oncology antibodies portfolio. The group will initially consist of a group of three experienced drug discovery and development professionals providing and building our pre-clinical development capacity. It will be headed by Dr Mike Gresser, who has recently joined the company’s Scientific Advisory Board.
The other two members of the pre-clinical group in the US are:
Dr David Fitzpatrick will lead the Preclinical Development team. Dr Fitzpatrick has extensive industry experience including seven years at Immunex and Amgen. His pre-clinical expertise includes several therapeutic antibody projects in asthma, arthritis and psoriasis, which he and his group helped advance into Phase I clinical trials. David has also spent more than 10 years undertaking biomedical research in Australia and Canada.
Dr Beatrice Perotti will lead the Preclinical Development Programs and be in charge of the business operations of the US Office of OGeS. Dr Perotti had received her PhD from UCSF and MBA from UCLA, and spent 13 years at Pfizer Central Research and Amgen Inc. Beatrice has broad experiences including early development team leadership and has led functional teams, as well as cross-functional matrix teams in both development and corporate business projects.
